Novartis halts trial of superbug drug

The Basel-based pharma company, Novartis, is to take a $235 million (SFr257.3 million) charge after stopping development of a treatment for bacterial infections.

This content was published on August 29, 2008 - 11:58

Novartis reported on Friday that its Aurograb medication had shown a lack of efficacy in mid-stage trials.

The charge, which reflects the full amount allocated to the project, will be taken in the company's third-quarter results.

Novartis acquired Aurograb in 2006 when it bought NeuTec Pharma, a specialist in fighting hospital superbugs, for nearly $570 million.

Another compound acquired with NeuTec, Mycograb, continues in late-stage trials for the treatment of a life-threatening fungal infection.

Analysts at JP Morgan said in a note that the move would have "no significant impact on Novartis, although [it would be] a small negative for sentiment".

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.